This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS chair in the [...]
EAST HANOVER, N.J., March 27, 2019 /PRNewswire/ --Novartis today announced that the US Food and Drug Administration (FDA) has approved [...]
- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis [...]
Brief Summary: Primary Objective: To determine the efficacy of SAR442168 in reducing the number of new brain lesions reported in [...]
NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE)—BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing [...]
Depression and psychological distress symptoms can have a huge effect on the way multiple sclerosis (MS) patients view their well-being, [...]
Lael Stone, age 59, Died peacefully on February 4, 2019, at the Maltz Hospice House, Beachwood, Ohio, surrounded by her family. She was [...]
NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative [...]
First Bruton’s Tyrosine Kinase inhibitor (BTKi) demonstrating clinical proof-of-concept in relapsing multiple sclerosis (RMS) [...]
Annualized Relapse Rate (ARR) of 0.07 observed for all patients on Phase 2 trial ECTRIMS data review conference call to be held [...]